BLCM - Enrollment underway for Bellicum's BPX-603 in early-stage solid tumor study

Bellicum Pharmaceuticals (BLCM) has announced enrollment and apheresis of the first patient in Phase 1/2 trial for BPX-603 in patients with solid tumors that express human epidermal growth factor 2.The trial will investigate the safety, tolerability, and activity of BPX-603, administered with rimiducid. Initial dose escalation phase will evaluate safety and identify the Phase 2 dose. The Phase 2 portion of the trial will assess the safety, pharmacodynamics, and clinical activity of BPX-603 in various HER2+ solid tumors.BPX-603 is Bellicum’s first dual switch GoCAR-T product candidate that incorporates the company’s iMC activation and CaspaCIDe safety switch technologies.Earlier this week, the FDA placed a clinical hold on another GoCAR-T candidate, after a patient death.Shares rise 3% in premarket.

For further details see:

Enrollment underway for Bellicum's BPX-603 in early-stage solid tumor study